Ibogaine treatment Oregon and Washington searches usually come down to one question: does either state's law allow it? In the official sources we read on 31 October 2026, neither state has a law that authorizes ibogaine treatment. Ibogaine is a Schedule I controlled substance in federal regulation. Washington's statute lists it by name, and Oregon's current rule adopts the federal Schedule I list. Oregon's psilocybin program covers psilocybin, and a 2026 Oregon bill that would have let physicians provide ibogaine did not pass. Washington's 2025 budget provides $10,000 for a University of Washington study of ibogaine-assisted therapy, and a separate bill for a three-year study has not passed. This page explains what each text says and does not say. It is general information, not legal advice, and it does not say whether any clinic or program is legal.
Federal law applies in both states
The Drug Enforcement Administration's list of Schedule I hallucinogenic substances includes ibogaine as entry (d)(21) of 21 CFR 1308.11, with the alternate name Tabernanthe iboga. The paragraph covers any material, compound, mixture or preparation containing any quantity of the listed substances, unless it is specifically excepted or listed in another schedule. We read that text on the eCFR through its public data service, which reported the title as up to date through 29 October 2026. A state program or study does not change that listing by itself. Federal action beyond the scheduling rule, and Texas law, are left to our separate guide on ibogaine's legal status in the US.
Oregon
The psilocybin program covers psilocybin. Oregon's Ballot Measure 109, passed in November 2020 and now codified as ORS 475A, directs the Oregon Health Authority to license and regulate the manufacturing, transportation, delivery, sale and purchase of psilocybin products, and the provision of psilocybin services. The Authority's program page does not mention ibogaine. The page also says that on 1 September 2026 Oregon Psilocybin Services and the Oregon Medical Marijuana Program merged into a new Medical Cannabis and Psilocybin Section. We could not read the text of ORS 475A itself, so this describes the Authority's own summary of it.
A 2026 ibogaine bill did not pass. The Authority's 2026 End-of-Session Legislative Report says the Legislature adjourned on Friday, 6 March 2026. Under "Notable Bills Not Passed" it lists HB 4110, Ibogaine, which it says would have authorized physicians to provide ibogaine to patients to treat various behavioral health concerns, under certain conditions. That is the Authority's own account. The Oregon Legislature's website refused our connection, so we did not read the bill's page, text or history, and we read no official page that shows a different outcome.
State schedules follow the federal ones. The Oregon Secretary of State's current text of OAR 855-080-0021, the Board of Pharmacy's Schedule I rule, says Schedule I consists of the drugs and other substances listed in 21 CFR 1308.11, which the rule cites by its 1 April 2025 edition, followed by Oregon's own additional entries. Because ibogaine appears in the federal section as we read it today, that incorporation places it in Oregon's Schedule I. The rule's history line shows its latest amendment was filed on 17 June 2026. We did not read the 1 April 2025 edition of the federal section.
Washington
State law lists ibogaine in Schedule I. RCW 69.50.204 lists "Ibogaine" among its Schedule I hallucinogenic substances, with Tabernanthe iboga given as a trade or other name. A nonpartisan Senate staff report on a 2025 ibogaine bill says the same thing in plain terms: ibogaine is listed as Schedule I under the state and federal Uniform Controlled Substances Acts.
The 2025 budget funds a study, not a treatment pathway. Chapter 424, Laws of 2025 (ESSB 5167, the operating budget, approved by the governor on 20 May 2025 with a partial veto) provides, in section 606(62), $10,000 of the workforce education investment account solely for the University of Washington to conduct a prospective, randomized cohort study between 1 July 2025 and 30 June 2027. The study is to determine whether ibogaine-assisted therapy conducted through a licensed clinic in North America, followed by structured therapeutic support, has advantages over treatment as usual for adults diagnosed with opioid use disorder. The university may use private philanthropic funding to help. The governor's veto message names only section 606(64), an unrelated item, within that section, so subsection (62) was not vetoed. The same chapter, in section 1602, which amends the 2024 supplemental budget, carries a $250,000 opioid abatement settlement account line for the university's Center for Novel Therapeutics in Addiction Psychiatry "for an initial study of ibogaine assisted therapy." We found no report of either study's progress or results. These provisions fund research. They do not say that ibogaine treatment is permitted outside a study.
A separate three-year study bill has not passed. SB 5204 would direct the University of Washington to run a three-year, prospective, randomized cohort study comparing ibogaine-assisted therapy with treatment as usual for adults with opioid use disorder, with the ibogaine therapy given at a licensed clinic in Mexico. The staff report lists its appropriation as none. According to the Legislature's bill page, it was prefiled on 9 January 2025, had a committee hearing on 6 February 2025, and was reintroduced and retained in its present status on 12 January 2026, with no later action recorded as of 31 October 2026. It has not passed.
The 2023 psilocybin law is about psilocybin. The final bill report for 2SSB 5263 (Chapter 364, Laws of 2023, with a partial veto) has the Health Care Authority establish a psilocybin task force, which must submit a final report by 1 December 2023. Subject to appropriation, it also has the University of Washington establish a psilocybin therapy services pilot by 1 January 2025 for first responders and veterans aged 21 or older. The summary we read describes only psilocybin. Separately, it notes that Colorado's Proposition 122 includes other substances such as DMT and ibogaine. We did not read the task force's report or learn whether the pilot was funded.
What the sources do not show
None of the official texts we read authorizes ibogaine treatment in Oregon or Washington. That is a statement about what we read, not proof that no other rule exists. We did not read the Oregon Legislature's bill pages, the text of ORS 475A, the 1 April 2025 edition of the federal rule that Oregon cites, or any Washington or Oregon agency guidance beyond what is cited here. Nor can a reading of statutes tell a person whether travel to a clinic elsewhere, or any particular activity, is lawful for them. That is a question for a lawyer.
Legal status is not a safety signal
A 2026 review in the journal Addiction describes a rare but clinically significant risk of prolonged QTc interval and potentially fatal ventricular arrhythmias with ibogaine, reports that these events have occurred at therapeutic doses and in people without known heart conditions, and says treatment should take place only under controlled medical supervision with rigorous cardiovascular monitoring. A state funding a study, or a bill being introduced, does not show that any setting is safe.
How this page was made
We read each source named here on 31 October 2026. The federal regulation came from the eCFR through its public data service. The Washington session law and two staff reports were read from text extracted from their PDFs, and several other pages were read through an automated summarizing tool, so the wording above is our paraphrase. We did not contact any clinic, agency or lawyer, and we list no clinics. Laws and bills change, so check current official sources before relying on this page. If you have a health question about ibogaine or about stopping a substance, talk with a qualified physician.
Evidence and Scope
Sources and Limits
These sources explain general treatment settings and questions. Check the services, professionals and arrangements of each program directly.
- Electronic Code of Federal Regulations, 21 CFR 1308.11 (DEA Schedule I)Text read on 2026-10-31 on the eCFR itself through its public versioner data service (title 21 reported up to date as of 2026-10-29); the website pages redirect automated readers to an unblock page, so the data service was used. Paragraph (d) lead-in and entry (d)(21) were read. Says nothing about state programs or about any clinic; the 2025-04-01 edition cited by Oregon's rule was not read.Observed
- Oregon Health Authority, Medical Cannabis and Psilocybin Section (program page describing ORS 475A and Ballot Measure 109)A state agency program page, classed official_law only because it is the nearest official source read for ORS 475A; the statute text itself (oregonlegislature.gov refused automated connections) was not read. Read through a summarizing fetch on 2026-10-31; paraphrases need a human check. A page that does not mention ibogaine does not prove the statute is silent on it.Observed
- Oregon Health Authority, 2026 End-of-Session Legislative ReportA state agency summary of bills it tracked, not the Legislature's own record. Text extracted locally from the PDF on 2026-10-31 (the page 'Notable Bills Not Passed' lists HB 4110, Ibogaine). The Oregon Legislature's bill page and bill text for HB 4110 refused automated connections on 2026-10-30 and 2026-10-31 and were not read, so the bill's full history and wording are unverified; a LegiScan entry seen only in search snippets (not opened, discovery only) was consistent with the report.Observed
- Oregon Secretary of State, Oregon Administrative Rules Database, OAR 855-080-0021 (Board of Pharmacy, Schedule I)Rule text and history read on 2026-10-31 on the Secretary of State's database (a summarizing fetch and a local download of the page). Subsection (1) incorporates 21 CFR 1308.11 'v. 04/01/2025' and adds Oregon entries; the page does not name ibogaine itself, so ibogaine's Oregon status rests on the incorporation. History shows the latest amendment filed 2026-06-17 (BP 6-2026). The 2025-04-01 edition of the federal section was not read, and no Board guidance was read.Observed
- Washington State Legislature, RCW 69.50.204 (Schedule I)Statute text read on 2026-10-31 through a summarizing fetch of the Legislature's RCW page, which shows bracketed former numbering and an amendment history ending [2022 c 16 s 53]; the page did not state a currency date in the portion returned, so confirm against the current RCW. Describes scheduling only; not a statement about any clinic.Observed
- Washington State Legislature, Chapter 424, Laws of 2025 (ESSB 5167, operating budget, partial veto), session law PDFSession law PDF downloaded on 2026-10-31 and read as extracted text (the file is very large; sections 606 and 1602 and the governor's veto message were read, and the rest was searched for 'ibogaine'). The text has no strikethrough or underline markup, so the 2024 budget line in section 1602 was identified as existing text by the absence of the double-parenthesis deletion marks. A funding line is not authorization for any treatment outside a study, and the text says nothing about progress or results.Observed
- Washington Senate Bill Report, SB 5204, as of 2025-02-05 (nonpartisan legislative staff)Staff analysis for legislators, not part of the bill and not a statement of legislative intent (it says so itself). Text extracted locally from the PDF on 2026-10-31. Describes the bill and the Schedule I listing as of 2025-02-05.Observed
- Washington State Legislature, SB 5204 (2025-26) bill textIntroduced bill text read on 2026-10-31 through a summarizing fetch; a bill that has not passed has no legal effect.Observed
- Washington State Legislature, bill summary and history for SB 5204Bill history read on 2026-10-31 through a summarizing fetch (the page's status line was 'as of Saturday, October 31, 2026'); status can change.Observed
- Washington Senate Final Bill Report, 2SSB 5263 (Chapter 364, Laws of 2023, partial veto)A staff summary read on 2026-10-31 through a summarizing fetch, not the session law text. It states what the act requires, not whether the task force reported or the pilot ran or was funded.Observed
- Addiction 2026;121(6):1616-1621, Brunt TM, PubMed record PMID 41560340, DOI 10.1111/add.70319Narrative review abstract read on the PubMed page on 2026-10-31; the full text was not read. Describes cardiac risk and supervision recommendations; no legal analysis, no clinic assessment, no individual medical advice. No qualified clinical review of this article is recorded.Observed